Industry Focus

Discussing the details behind the FDA's negative vote on Sarepta's DMD drug and Gilead Sciences' sliding hepatitis C sales.

Direct download: 05042016_IF_HEalthcare.mp3
Category:Podcast -- posted at: 1:09pm EDT

1